February 08, 2007
Children's Hospital of Orange County (CHOC) is one of 15 institutions worldwide recently selected as a "major affiliate" of the Type 1 Diabetes TrialNet Network, which studies the development, prevention and early treatment of type 1 diabetes. This distinction places CHOC at the international forefront of diabetes research.
Currently, CHOC is one of nine sites conducting a study assessing the efficacy of nutritional supplementation during pregnancy and shortly after birth. Researchers at the CHOC Research Institute are studying whether supplementation alters the immune system and prevents the onset of type 1diabetes in babies determined to be at high risk because of family history of the disease.
Since close blood relatives face increased risk (10 - 15 times greater) of developing type 1 diabetes, the results could have profound implications. An estimated three to four percent of family members of people with type 1 diabetes also have autoantibodies. These autoantibodies serve as a marker for early destruction of the insulin-producing cells.
"Our goal is to identify the people at highest risk and find out if intervention with early nutrition supplements can alter the role of diabetes later on," says pediatric endocrinologist Mark Daniels, M.D., who serves as principal investigator for the TrialNet study at CHOC. "We will soon begin another prevention study assessing the efficacy of oral insulin in decreasing the chances of high-risk individuals converting to diabetes."
Two years ago, CHOC played a key role in the research and care for the very first patient enrolled in the TrialNet study. According to Dr. Daniels, " 'Major Affiliate' status will allow us to expand dramatically so we can offer these studies to more patients and families, with a greater reach into the community. It will give CHOC more resources to identify families at risk for diabetes, and to apply our research and knowledge."
About CHOC Children's: Named one of the best children’s hospitals by U.S. News & World Report (2013-2014) and a 2013 Leapfrog Top Hospital, CHOC Children's is exclusively committed to the health and well-being of children through clinical expertise, advocacy, outreach and research that brings advanced treatment to pediatric patients. Affiliated with the University of California, Irvine, CHOC’s regional healthcare network includes two state-of-the-art hospitals in Orange and Mission Viejo, several primary and specialty care clinics, a pediatric residency program, and four centers of excellence - The CHOC Children’s Heart, Neuroscience, Orthopaedic and Hyundai Cancer Institutes. CHOC earned the Gold Level CAPE Award from the California Council of Excellence, the only children’s hospital in California to ever earn this distinction, and was awarded Magnet designation, the highest honor bestowed to hospitals for nursing excellence. Recognized for extraordinary commitment to high-quality critical care standards, CHOC’s Pediatric Intensive Care Unit (PICU) is the first in the United States to earn the Pediatric Beacon Award for Critical Care Excellence.
Denise Almazan, Director of Public Relations
phone: (714) 509-8680